ZA988664B - Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions - Google Patents
Secretory leukocyte protease inhibitor dry powder pharmaceutical compositionsInfo
- Publication number
- ZA988664B ZA988664B ZA988664A ZA988664A ZA988664B ZA 988664 B ZA988664 B ZA 988664B ZA 988664 A ZA988664 A ZA 988664A ZA 988664 A ZA988664 A ZA 988664A ZA 988664 B ZA988664 B ZA 988664B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compositions
- dry powder
- protease inhibitor
- powder pharmaceutical
- secretory leukocyte
- Prior art date
Links
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 title 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/943,759 US20010006939A1 (en) | 1997-10-03 | 1997-10-03 | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA988664B true ZA988664B (en) | 1999-04-06 |
Family
ID=25480210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA988664A ZA988664B (en) | 1997-10-03 | 1998-09-22 | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
Country Status (9)
Country | Link |
---|---|
US (2) | US20010006939A1 (ja) |
EP (2) | EP1030683A1 (ja) |
JP (2) | JP2001518518A (ja) |
KR (1) | KR20010024395A (ja) |
CN (1) | CN1327452A (ja) |
AU (2) | AU738298B2 (ja) |
CA (1) | CA2308123A1 (ja) |
WO (2) | WO1999017800A1 (ja) |
ZA (1) | ZA988664B (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043308A2 (en) * | 1998-02-27 | 1999-09-02 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
JP5704780B2 (ja) * | 1999-08-13 | 2015-04-22 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 脈管形成因子の用量および心筋血流を改善するための投与方法 |
AU7957700A (en) | 1999-10-26 | 2001-05-08 | Japan Tissue Engineering Co., Ltd. | Wound contraction inhibitors |
AU1628101A (en) * | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
WO2001051030A1 (en) * | 2000-01-10 | 2001-07-19 | Dura Pharmaceuticals, Inc. | Pharmaceutical formulation and method for pulmonary and oral delivery |
WO2001052883A1 (en) * | 2000-01-20 | 2001-07-26 | Amgen Inc. | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
AU2001241913A1 (en) * | 2000-03-01 | 2001-09-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for wound treatment |
WO2001092522A2 (en) * | 2000-06-01 | 2001-12-06 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
DE10101792B4 (de) * | 2001-01-17 | 2004-03-18 | Vivotec Biomedical Technologies Gmbh | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern |
JP5154732B2 (ja) * | 2001-02-06 | 2013-02-27 | イノバータ・バイオメッド・リミテッド | 薬剤 |
WO2003018620A2 (en) * | 2001-08-27 | 2003-03-06 | Les Laboratoires Aeterna Inc. | Serine protease inhibitor and processes for the preparation thereof |
EP1479300B1 (en) * | 2002-02-22 | 2009-10-21 | Ajinomoto Co., Inc. | Amino acid powder and process for producing the same |
GB0226274D0 (en) * | 2002-11-11 | 2002-12-18 | Medpharm Ltd | Metered dose inhalation preparations |
GB0309064D0 (en) * | 2003-04-22 | 2003-05-28 | Univ Manchester | Modified peptides and their uses |
EP1660661A2 (en) * | 2003-08-08 | 2006-05-31 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
SI1656455T1 (sl) * | 2003-08-13 | 2012-12-31 | Sandoz Ag | Postopek za čiščenje rekombinantnih polipeptidov |
CA2545855A1 (en) * | 2003-11-14 | 2005-06-02 | Baxter International Inc. | Alpha 1-antitrypsin compositions and treatment methods using such compositions |
GB0328629D0 (en) * | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
AU2005221151A1 (en) | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
US20060134008A1 (en) * | 2004-12-16 | 2006-06-22 | Daniel Deaver | Compositions and methods for pulmonary conditions |
CN101401001A (zh) * | 2006-01-12 | 2009-04-01 | 詹森药业有限公司 | 分泌性白细胞蛋白酶抑制剂通过糜酶的加工 |
US8725529B2 (en) * | 2008-12-30 | 2014-05-13 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US8712794B2 (en) * | 2008-12-30 | 2014-04-29 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US8706518B2 (en) * | 2008-12-30 | 2014-04-22 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100168525A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US8694330B2 (en) * | 2008-12-30 | 2014-04-08 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100168602A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US20100163038A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US9750903B2 (en) * | 2008-12-30 | 2017-09-05 | Gearbox, Llc | Method for administering an inhalable compound |
US20100163036A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US8738395B2 (en) * | 2008-12-30 | 2014-05-27 | The Invention Science Fund I, Llc | Methods and systems for presenting an inhalation experience |
US20100163024A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation | Methods and systems for presenting an inhalation experience |
US20100163025A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
US20100163027A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100168529A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100163033A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100169259A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100163034A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting an inhalation experience |
US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
RU2657523C2 (ru) * | 2011-11-03 | 2018-06-14 | Олег Петрович Жирнов | Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение |
AU2018261021A1 (en) * | 2017-05-05 | 2019-12-12 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
WO2019046664A1 (en) * | 2017-08-30 | 2019-03-07 | Applied Biological Laboratories, Inc. | COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE556587A (ja) * | 1957-01-31 | 1957-04-11 | ||
US4678812A (en) * | 1986-05-30 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
JP3385040B2 (ja) * | 1991-02-14 | 2003-03-10 | 武田薬品工業株式会社 | グリア活性化因子およびその製造法 |
US6005100A (en) * | 1992-12-02 | 1999-12-21 | Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo | Trehalose composition for prolonging product shelf life |
JP3168550B2 (ja) * | 1992-12-02 | 2001-05-21 | 株式会社林原生物化学研究所 | 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品 |
UA46706C2 (uk) * | 1993-03-26 | 2002-06-17 | Амген Інк. | Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція |
US5633227A (en) * | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5876992A (en) * | 1996-07-03 | 1999-03-02 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
-
1997
- 1997-10-03 US US08/943,759 patent/US20010006939A1/en not_active Abandoned
-
1998
- 1998-08-19 WO PCT/US1998/017173 patent/WO1999017800A1/en not_active Application Discontinuation
- 1998-08-19 JP JP2000514669A patent/JP2001518518A/ja not_active Withdrawn
- 1998-08-19 CA CA002308123A patent/CA2308123A1/en not_active Abandoned
- 1998-08-19 AU AU89149/98A patent/AU738298B2/en not_active Ceased
- 1998-08-19 EP EP98940994A patent/EP1030683A1/en not_active Withdrawn
- 1998-08-28 CN CN98811819A patent/CN1327452A/zh active Pending
- 1998-08-28 EP EP98941096A patent/EP1025122A1/en not_active Withdrawn
- 1998-08-28 JP JP2000514935A patent/JP2001519142A/ja not_active Withdrawn
- 1998-08-28 AU AU89239/98A patent/AU8923998A/en not_active Abandoned
- 1998-08-28 KR KR1020007003605A patent/KR20010024395A/ko not_active Application Discontinuation
- 1998-08-28 WO PCT/US1998/017919 patent/WO1999018128A1/en not_active Application Discontinuation
- 1998-09-22 ZA ZA988664A patent/ZA988664B/xx unknown
-
2001
- 2001-06-29 US US09/896,685 patent/US20020010318A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1030683A1 (en) | 2000-08-30 |
AU8923998A (en) | 1999-04-27 |
US20020010318A1 (en) | 2002-01-24 |
JP2001519142A (ja) | 2001-10-23 |
AU8914998A (en) | 1999-04-27 |
AU738298B2 (en) | 2001-09-13 |
KR20010024395A (ko) | 2001-03-26 |
US20010006939A1 (en) | 2001-07-05 |
EP1025122A1 (en) | 2000-08-09 |
CA2308123A1 (en) | 1999-04-15 |
WO1999018128A1 (en) | 1999-04-15 |
WO1999017800A1 (en) | 1999-04-15 |
JP2001518518A (ja) | 2001-10-16 |
CN1327452A (zh) | 2001-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA988664B (en) | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions | |
HUP0104768A3 (en) | 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same | |
HUP0105077A3 (en) | Serine protease inhibitors and pharmaceutical compositions containing them | |
PL331531A1 (en) | Pharmaceutical aerosol compositions | |
ZA983843B (en) | Protease inhibitors | |
PL336589A1 (en) | Serinic protease inhibitors | |
GB9727053D0 (en) | Pharmaceutical compositions | |
CY2569B1 (en) | Pharmaceutical compositions | |
HUP0002247A3 (en) | Protease inhibitors | |
PL337755A1 (en) | Protease inhibitors | |
IL132629A0 (en) | Protease inhibitors | |
HK1021700A1 (en) | Novel powder compositions | |
ZA988479B (en) | Protease inhibitors | |
IL131995A0 (en) | Gastric-retained pharmaceutical compositions | |
GB9723985D0 (en) | Pharmaceutical compositions | |
ZA9811532B (en) | Pharmaceutical compositions | |
ZA988064B (en) | Protease inhibitors | |
IL122591A0 (en) | Pharmaceutical compositions comprising cystein protease inhibitors | |
HU9700632D0 (en) | Pharmaceutical compositions | |
HUP0001976A3 (en) | Antiviral protease inhibitors and pharmaceutical compositions | |
EP0975612A4 (en) | PROTEASE INHIBITORS | |
ZA982117B (en) | Pharmaceutical compositions | |
GB9718270D0 (en) | Pharmaceutical compositions | |
GB9722066D0 (en) | Pharmaceutical compositions | |
GB9710527D0 (en) | Pharmaceutical compositions |